ClinicalTrials.gg
RecruitingNCT05808335Updated Jun 15, 2023

A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

A Phase 2 interventional study of Standard of care in Chronic Hepatitis B, sponsored by ImmuneMed, Inc.. Recruiting at 4 sites in Korea, Republic of. Open to participants aged 19 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by ImmuneMed, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jan 2022, registered Mar 2023).
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of — 4 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Korea, Republic of.

Planned enrollment
115th of 126
32 · median 106
Started
2022
with 4 others
Phase 2
31 of 149
2 open now
Registered
141st of 149
by date

Among the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of, this one is the 115th largest by planned enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2022, is one of 31 in phase 2, and was the 141st registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel group, 48-week follow-up, Phase IIa clinical study. This study has been designed to evaluate the change in HBsAg (log10 IU/mL) after administration of hzVSF-v13 50 mg/dose and hzVSF-v13 200 mg/dose in combination with an oral antiviral agent (Tenofovir or entecavir, including salt-free or salt-modifying drugs) compared to an oral antiviral agent in combination with a placebo (normal saline) in patients with chronic hepatitis B who are stably receiving an oral antiviral agent (Tenofovir or entecavir, including salt-free or salt-modifying drugs) for at least 24 weeks.

Read the detailed description

Among the subjects who provided a voluntary written consent to participate in this clinical study, the patients with chronic hepatitis B who are stably receiving an oral antiviral agent (Tenofovir or entecavir, including salt-free or salt-modifying drugs) for at least 24 weeks prior to the screening visit can be considered as potential subjects of this study. Only the subjects who completed the final eligibility evaluation at the baseline visit (Visit 2) after the screening tests will be randomized to the hzVSF-v13 50 mg combination group, hzVSF-v13 200 mg combination group (study group) and placebo combination group (control group) at a 1:1:1 ratio at each site. The randomized subjects will receive intravenous administration of hzVSF-v13 or the placebo to match hzVSF-v13 four times with 4 weeks interval for a total of 12 weeks, and oral administration of 1 tablet of an oral antiviral agent will be given once daily for a total of 48 weeks.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Those who have a history of a diagnosis of chronic more than 24 weeks prior to screening and have been maintaining HBsAg positive at screening
  2. Those who have an HBV DNA level that is below \<20 IU/mL
  3. Those who have been receiving tenofovir (including Tenofovir's salt-free or salt-modifying drugs), or entecarvir (including Entecavir's salt-free or salt-modifying drugs) stably for ≥24 weeks prior to screening and anticipated to maintain the identical drug with equivalent dosage and administration during the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of chronic liver disease caused by other than chronic infection at the time of screening
  2. Patients with a signs of loss of liver function and decompensation of liver disease
  3. Patients with uncontrolled diabetes ( >7.5%)
  4. Patients with uncontrolled hypertension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Placebo comparator
    Placebo to hzVSF-v13

    Placebo to match hzVSF-v13 + oral antiviral agent

    Drug: Standard of care

  • Experimental
    hzVSF-v13 50mg

    hzVSF-v13 50 mg/dose + oral antiviral agent

    Drug: Standard of care

  • Experimental
    hzVSF-v13 200mg

    hzVSF-v13 200 mg/dose + oral antiviral agent

    Drug: Standard of care

  • Experimental
    hzVSF-v13 800mg

    hzVSF-v13 800 mg/dose + oral antiviral agent

    Drug: Standard of care

Interventions

  • DrugStandard of care

    The following medications listed are allowed to be administered during the course of the clinical study. 1. Tenofovir (including salt-free or salt-modifying drugs) 2. Entecavir (including salt-free or salt-modifying drugs)

06

What researchers measure

Primary outcomes

  1. Change in HBsAg from the baseline at 24 weeks (log10 IU/mL)

    Baseline statistics for the changes in HBsAg (log10 IU/mL) from the baseline at 24 weeks shall be presented for each group, and a two-sample t-test or the Wilcoxon rank-sum test shall be performed to test differences of each study group compared to the control group.

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of subjects with HBsAg loss or seroconversion compared to the baseline at 8, 12, 24 and 48 weeks

    The number and percentage of subjects and 95% confidence interval for each treatment group and each evaluation time point shall be presented, and a chi-squared test or the Fisher's exact test shall be performed to test intergroup differences of each study group compared to the control group.

    Time frame: 8, 12, 24, 48 weeks

  2. Percentage of subjects with HBV DNA lower than the lower limit of quantification (LLOQ) compared to the baseline at 24 and 48 weeks

    The number and percentage of subjects and 95% confidence interval for each treatment group and each evaluation time point shall be presented, and a chi-squared test or the Fisher's exact test shall be performed to test intergroup differences of each study group compared to the control group.

    Time frame: 24, 48 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — It will be depending on internal discussion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Mar 2024, 26 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 26 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 11, 2023
StartActual
Jan 11, 2022
Primary completionEst.
Mar 27, 2024
CompletionEst.
Dec 4, 2024
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05808335
Lead sponsor
ImmuneMed, Inc.
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Jan 11, 2022
Primary completion
Mar 27, 2024 (estimated)
Completion
Dec 4, 2024 (estimated)
Last update
Jun 15, 2023

Study contacts

Sungman Park, Ph.D.
Contact
smpark@immunemed.co.kr
82-33-258-6563 ext. 6563
Joon Hyeok Lee, M.D. Ph.D.
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion